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Abstract

Literature Review

• Introduction: Preeclampsia during pregnancy warrants therapy
with low dose aspirin. The purpose of this review is to
investigate if these women are at increased future risk for
cardiovascular morbidity and mortality, and if aspirin therapy
prevents future cardiovascular events.
• Research Questions: Do women who had preeclampsia during
pregnancy have increased future cardiovascular morbidity and
mortality?
• Does continued aspirin use in postpartum women, who had
preeclampsia during pregnancy, decrease future cardiovascular
morbidity and mortality?
• Research Methods: Literature review was conducted utilizing
CINAHL, Dynamed plus and PubMed databases.
• Discussion: Many studies have found that preeclampsia does
increase risk of cardiovascular morbidity and mortality, but this
difference is not statistically significant until later decades in life.
There is also new evidence that the risks of bleeding from
prophylactic aspirin therapy outweigh the benefit of decreasing
cardiovascular and ischemic events. Based on this information,
it is prudent to further research and study this group and stratify
their risk as well as researching if there is a better modality upon
which to provide prophylaxis with lower risk than benefit.
• Keywords: Aspirin, Preeclampsia, Effect on endothelium, postpartum, future cardiovascular risk

Preeclampsia effect on endothelium
•Chambers et al. (2001) conducted a study designed to extrapolate maternal
versus placental factors contributing to the development of preeclampsia.

Introduction
Approximately 3-7% of pregnancies are affected by preeclampsia
(Sarma, et al, 2016). These pregnancies are higher risk due to the
hypertensive effects on the mother and fetus. There are
recommendations for preeclamptic women to take 81 mg aspirin,
daily, for prevention of negative fetal and maternal outcomes.
Hypertension leads to increased cardiovascular morbidity and
mortality (Sutters, 2018). Currently, there is a lack of evidence for
treatment beyond the post-partum period. This review investigates
if continued aspirin therapy helps to reduce future cardiovascular
morbidity and mortality in patients who were diagnosed with
preeclampsia during their pregnancy.

Statement of the Problem
Preeclampsia involves a hypertensive state, which increases the
shear against the endothelium of blood vessels. This predisposes
these women to thrombotic and ischemic events. This problem is
two-fold. One, we must understand if this group is at increased
future risk of cardiovascular morbidity and mortality. Two, is there a
treatment that decreases this risk. This knowledge holds the
potential of revealing a population in which we can intervene to
produce better cardiovascular outcomes.

•Heidema et al. (2015) investigated if having history of preeclampsia versus
obesity had a larger impact on the development of metabolic syndrome later in
life.
• They found the incidence of developing metabolic syndrome was
statistically significant in those with history of preeclampsia, compared
to those who were obese (P<0.001).
•Spaanderman et al. (2005) found that formerly preeclamptic women had a
15% increase in platelet responsiveness, demonstrating endothelial
dysfunction to some degree.
• They hypothesize that endothelial shear from the transient
hypertension of preeclampsia increases the number of presensitized
platelets, contributing to the hyperactive platelet activity of these
patients.
Aspirin effect on endothelium
•Hashemi et al. (2016) utilized flow-mediated brachial artery dilation, in a tripleblind randomized control trial, to evaluate how aspirin affects endothelial
function of preeclamptic patients following pregnancy.
•

They found antioxidant effects of aspirin decrease oxidative injury to
the endothelium, decreasing platelet activation.
•The evidence by Hashemi et al. (2016), and Spaanderman et al. (2005)
demonstrate that aspirin decreases platelet responsiveness by more than one
mechanism.
• Decreased endothelial shear and platelet response.
Long term cardiovascular outcomes
•Bokslag et al. (2017) and Funai et al. (2005), discovered formerly preeclamptic
women are at increased future cardiovascular morbidity and mortality, starting
in the 5th and 3rd decades (respectively) following delivery.
• Bokslag et al. (2017) found 42% of their formerly preeclamptic
subjects met their defined criteria to require early preventative
measures, compared to their counterparts (P<0.0001).
•

Funai et al. (2005) had results showing in 24-36 years of follow up is
when the risk of death more than doubled in women who were
preeclamptic in the past.
•Grandi et al. (2017) found formerly preeclamptic women were at higher risk of
developing cardiovascular disease later in life, demonstrated by a hazard ratio
of 2.2, and 95% confidence interval.
•Leslie et al. (2016) conducted a well-defined meta-analysis in which the
literature shows formerly preeclamptic women have a 2x increased risk of
developing cardiovascular disease and mortality.
•

•Wikstrom et al. (2005) also found statistically significant increase in future
cardiovascular disease.
• Wikstrom et al. (2005) utilized IRRs and 95% CI for statistical analysis
and the adjusted IRR for ischemic disease in women with
hypertension during multiple pregnancies was statistically significantly
higher than women who only experienced hypertension during their
first pregnancy (P<0.044).
Aspirin effect on long term cardiovascular outcomes following
preeclampsia
•Sarma et al. (2016) found there is a 12% decrease in cardiovascular events
and 17% decrease in stroke, however, due to increased bleeding risk with
aspirin therapy for primary prevention, the benefit of aspirin therapy was 0.3%,
showing little benefit.
•

Research Questions
1. Do women who had preeclampsia during pregnancy have
increased future cardiovascular morbidity and mortality?
2. Does continued aspirin use in postpartum women, who had
preeclampsia during pregnancy, decrease future
cardiovascular morbidity and mortality outcomes?

This risk is further increased with gestation longer than 37 weeks. (RR,
0.98; 95%CI, 0.5-1.92)

Aspirin use for secondary prevention shows 14% decrease in allcause mortality (HR 0.86).

•McNeil et al. (2018) found that aspirin use significantly decreased
cardiovascular events (HR 0.89, 95% CI, 0.77 to 1.03). However, risk for major
hemorrhagic events was also significantly higher in the aspirin group.
•The findings in these two large studies demonstrate that the risk of
hemorrhagic event from aspirin therapy outweighs the benefits when used for
primary prevention.
•More research is necessary to further extrapolate if preeclampsia would make
this secondary prevention.

Discussion
To evaluate if preeclampsia leads to future cardiovascular risk,
and if aspirin decreases that risk, is multi-fold. First, one must
understand the vascular physiology of aspirin and preeclampsia.
In regard to how preeclampsia affects endothelial health, the
information is lacking and more studies are needed to
differentiate which mechanisms are leading to endothelial
dysfunction in this population. Chambers et al. (2001), Heidema
et al. (2015) and Spaanderman et al. (2005) all found that
preeclampsia leads to endothelial dysfunction and increased
platelet activity. More research is necessary to determine the
validity of these results and increase the understanding of these
mechanisms at play.
Aspirin has been theorized to have mechanisms interacting with
the oxidative damage to the endothelium and decreasing
platelet activity following endothelial injury. Hashemi et al.
(2016), and Spaanderman et al. (2005) found that aspirin works
by more than one mechanism to alter endothelial physiology
and improve vascular health. Again, further research is needed
to validate these results.
Investigating the long term cardiovascular effects following
preeclampsia is more of a challenge due to the longevity of a
studied required to produce high quality results. From the
available literature, only a few studies are of the quality and
sample size in which to make a broad generalization to the postpreeclamptic population. Of these, it has been found that in fact,
these women have increased cardiovascular morbidity and
mortality, however, not until the 3rd-5th decades following delivery
(Funai et al., 2005, and Bokslag et al., 2017). Many of the
available information is based on retrospective studies and
evaluation from a hospital database. As there is variation
amongst the studies regarding inclusion and exclusion criteria, it
is not always clear what other variables are present in the lives
of these subjects that may predispose them to increased
cardiovascular morbidity and mortality. There continues to be a
need for stronger studies as it appears there is a population that
can benefit from preventative therapy to decrease
cardiovascular events and thus decrease healthcare costs to
both the patient and the healthcare system as a whole.
When studying if aspirin is an appropriate therapy for prevention
in this population, it is important to keep in mind that they are
not at increased risk until later in life. Aspirin effect in an elderly
population is warranted when weighing the risks versus benefits
of aspirin therapy in this population. The information from Sarma
et al. (2016), and McNeil et al. (2018) demonstrate long term
aspirin use for primary prevention has higher risk to benefit ratio.
It is important for future research to investigate if preeclampsia
makes aspirin use in this population “primary” or “secondary”
prevention.
There are many unknown variables that need to be considered
when trying to solve this question in regard to the postpreeclamptic population. First, more information is needed to
definitively determine the pathophysiology of preeclampsia. This
understanding will guide researchers in evaluating future risks.
Second, determination of future risk in this population. This
research should include large, long-term studies with a diverse
sample population. It is astute to also control for other variables
that lead to cardiovascular disease.
It is upon the healthcare research community to provide sound
studies and our duty as medical professionals to better serve
this population. Little remains known about the pathophysiology
of this group, let alone how that affects their future risk. It is our
duty to provide these women with the best care possible.

Application to Clinical Practice
The clinical implications of this is important as there may be a
subset that is at increased risk that could benefit from
preventative measures. Understanding comes two fold in this
investigation. First, determining if this population is at increased
future risk and second, if aspirin is the appropriate preventive
therapy for this population. The longevity required in a study of
this nature has potential for high drop-out rates which will skew
results. However, this information is important as there is
potential to decrease burden on the healthcare system and
potential for saving healthcare dollars by preventing major
cardiovascular events if this population has been undertreated.
Current research remains inconclusive at this time. More studies
are required to provide good evidence upon which to base
practice recommendations. Determining the answers to these
questions allows us as healthcare providers to better serve
these patients. Not only will this knowledge and further
understanding benefit the health of the patient, it has potential to
decrease healthcare dollars and the burden placed on the
healthcare system by preventing major cardiovascular events.
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